PRE 📈 Prenetics Global - Overview
Exchange: NASDAQ • Country: Hong Kong • Currency: USD • Type: Common Stock • ISIN: KYG722451062
PRE: DNA tests, Cancer detection, Genomic profiling, Liquid biopsy, Wellness products
Prenetics Global Limited, a health sciences company, focuses on advancing consumer and clinical health. The company's consumer initiatives is led by IM8, a new health and wellness brand. Its prevention arm, CircleDNA, uses next-generation sequencing (NGS) technology to offer comprehensive consumer DNA test. It also develops and commercializes multi-cancer early detection technologies. In addition, the company offers a range of genomic profiling panels tailored for requirements and clinician needs, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests. Further, the company offers ACTLiquid Pro, a sequencing based liquid biopsy assay for pan-solid tumors; ACTMonitor, which provides real time monitoring of drug resistance, treatment response, and cancer recurrence; and ACT Risk, which manages the cancer risk. Additionally, it is involved in the sports distribution activities providing sports nutrition products to fitness facilities. The company operates in Taiwan, Hong Kong, the United Kingdom, and internationally. The company was founded in 2014 and is based in Quarry Bay, Hong Kong and has a presence in the United States. Web URL: https://www.prenetics.com
Additional Sources for PRE Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PRE Stock Overview
Market Cap in USD | 63m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC Sub-Industry | Reinsurance |
IPO / Inception | 2022-05-18 |
PRE Stock Ratings
Growth 5y | -77.0% |
Fundamental | -76.7% |
Dividend | - |
Rel. Strength Industry | -46.7 |
Analysts | 5/5 |
Fair Price Momentum | 4.10 USD |
Fair Price DCF | - |
PRE Dividends
No Dividends PaidPRE Growth Ratios
Growth Correlation 3m | 56.8% |
Growth Correlation 12m | -8.3% |
Growth Correlation 5y | -93.5% |
CAGR 5y | -59.24% |
CAGR/Mean DD 5y | -0.91 |
Sharpe Ratio 12m | 0.38 |
Alpha | -14.46 |
Beta | 0.52 |
Volatility | 84.02% |
Current Volume | 10.4k |
Average Volume 20d | 13.3k |
What is the price of PRE stocks?
As of December 22, 2024, the stock is trading at USD 5.65 with a total of 10,443 shares traded.
Over the past week, the price has changed by +6.54%, over one month by +20.35%, over three months by +25.60% and over the past year by +15.28%.
As of December 22, 2024, the stock is trading at USD 5.65 with a total of 10,443 shares traded.
Over the past week, the price has changed by +6.54%, over one month by +20.35%, over three months by +25.60% and over the past year by +15.28%.
Is Prenetics Global a good stock to buy?
No, based on ValueRay Fundamental Analyses, Prenetics Global (NASDAQ:PRE) is currently (December 2024) a stock to sell. It has a ValueRay Fundamental Rating of -76.70 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PRE as of December 2024 is 4.10. This means that PRE is currently overvalued and has a potential downside of -27.43%.
No, based on ValueRay Fundamental Analyses, Prenetics Global (NASDAQ:PRE) is currently (December 2024) a stock to sell. It has a ValueRay Fundamental Rating of -76.70 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PRE as of December 2024 is 4.10. This means that PRE is currently overvalued and has a potential downside of -27.43%.
Is PRE a buy, sell or hold?
Prenetics Global has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy PRE.
Prenetics Global has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy PRE.
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for PRE stock price target?
According to ValueRays Forecast Model, PRE Prenetics Global will be worth about 4.5 in December 2025. The stock is currently trading at 5.65. This means that the stock has a potential downside of -20.71%.
According to ValueRays Forecast Model, PRE Prenetics Global will be worth about 4.5 in December 2025. The stock is currently trading at 5.65. This means that the stock has a potential downside of -20.71%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 9 | 59.3% |
Analysts Target Price | 6.2 | 10.3% |
ValueRay Target Price | 4.5 | -20.7% |